

Pseudotyped VSV-EBOV Glycoprotein-ΔG-Luciferase (PSVCD101)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview	Recombinant Vesicular Stomatitis Virus pseudotyped Ebola glycoprotein (rVSV pseudotyped EBOV GP) system in which the G protein of VSV has been deleted, replaced with firefly luciferase and used to produce VSV pseudotypes containing the envelope glycoprotein of Ebola virus. Since the infectivity of rVSV pseudotyped EBOV GP is restricted to a single round of replication, analyses of viral entry can be performed using just biosafety level 2 (BSL-2) containment. Infectivity and neutralization of infectivity can be measured by luciferase activity.
Antigen Description	Ebola glycoprotein
Species	Ebola Virus
Concentration	1.97E+08 RLU/ml
Size	20 µl
Buffer	DMEM, 1% FBS, L-glutamine and Penicillin/Streptomycin
Storage	Store at -80°C . Multiple freeze/thaw cycles not recommended. When using the virus, transfer the virus from the -80°C refrigerator and melt it in an ice bath.
Ship	Frozen on dry ice

BACKGROUND

Keywords	EBOV; Ebola glycoprotein; Ebola virus; Ebola virus glycoprotein; EBOV GP; Ebola virus Pseudovirus; EBOV Pseudovirus; Pseudovirus

GENE INFORMATION

45-1 Ramsey Road, Shirley, NY 11967, USA
Email: info@creative-diagnostics.com
Tel: 1-631-624-4882 Fax: 1-631-938-8221

References

1. Whitt, M.A., Generation of VSV pseudotypes using recombinant DeltaGVSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J. Virol. Methods, 2010. 169(2): p. 365-74.
2. Howell, K.A., et al., Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus. Cell Reports, 2017. 19(2): p. 413-424.

45-1 Ramsey Road, Shirley, NY 11967, USA

Email: info@creative-diagnostics.com

Tel: 1-631-624-4882 Fax: 1-631-938-8221